[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Galderma R&D\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":230},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,42,65,90,113,139,158,184,207],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100641772","phase-2-pharmacokinetics-safety-and-efficacy-of-nemolizumab-in-participants-aged-6-to-23-months-with-moderate-to-severe-atopic-dermatitis-100641772",false,"NCT07660835","Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis","A Multicenter, Open-Label, Single-Group Clinical Study to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric Subjects (Aged 6 to 23 Months) With Moderate-to-Severe Atopic Dermatitis Not Adequately Controlled With Topical Therapy","NemoBaby","Inclusion Criteria\n\n* Participants greater than and equal to (\\>=) 6 to less than (\\\u003C) 24 months of age at the screening visit.\n* Diagnosis of AD according to the American Academy of Dermatology Consensus Criteria at the time of the screening visit.\n* Eczema Area and Severity Index (EASI) score \\>= 16 at both screening and baseline visits.\n* Investigator's Global Assessment (IGA) score \\>= 3 (based on the IGA scale ranging from 0 to 4, in which 3 is moderate and 4 is severe) at both screening and baseline visits.\n* AD involvement \\>= 10 percent (%) of body surface area (BSA) at both screening and baseline visits. (Note: BSA to be derived from the SCORing Atopic Dermatitis (SCORAD).)\n* Weekly average of worst scratch\u002Fitch Numeric Rating Scale (WSI-NRS) score of at least 4 at both screening and baseline visits as assessed by the parent(s)\u002Fcaregiver:\n\n  * Screening WSI-NRS score will be determined by a single WSI-NRS assessment (score ranging from 0 to 10) for the 24-hour period immediately preceding the screening visit.\n  * Baseline WSI-NRS score will be determined based on the average of daily WSI-NRS scores (score ranging from 0 to 10) during the 7 days immediately preceding baseline (rounding not permitted). A minimum of 4 daily scores out of the 7 days immediately preceding baseline is required for this calculation. For participants who do not have at least 4 daily scores reported during the 7 days immediately preceding the planned enrollment date, enrollment should be postponed until this requirement is met, without exceeding the maximum screening duration of 4 weeks.\n* Documented history by a physician and\u002For investigator of inadequate response to existing topical AD medications or use of systemic therapies for control of the disease (within 6 months before the screening visit).\n* Participant's parent(s)\u002Fcaregiver willing and able to comply with all time commitments and procedural requirements of the clinical study protocol.\n* Participant's parent(s)\u002Fcaregiver understand and sign a parental Informed Consent Form (ICF) before any study-related procedures are performed.\n* Participant's parent(s)\u002Fcaregiver agree to apply a moisturizer daily from the screening visit and liberally as needed throughout the study; if applying a prescribed topical corticosteroid (TCS) prior to study enrollment, agree to continue at the same stable dose from screening and throughout the study as determined appropriate by the investigator.\n\nExclusion Criteria\n\n* Body weight \\\u003C 5 Kilograms (kg).\n* Child in Care: a child placed under the control or protection of an agency, organization, institution, or entity by courts or government authorities under applicable law or regulation.\n* Cutaneous infection within 1 week before the baseline visit or any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics, or antifungals within 2 weeks before the baseline visit. Participants may be rescreened once the infection has resolved.Note: A participant with mild, localized superficial infection may be included based on investigator discretion.\n* Having received any of the following treatments within the specified timeframe before the baseline visit:\n\nCoal tar products - 2 weeks Topical Janus kinase (JAK) inhibitor - 2 weeks Topical phosphodiesterase-4 (PDE-4) inhibitor - 2 weeks Medium and higher potency TCS - 2 weeks Topical calcineurin inhibitor (TCI) - 2 weeks Topical medications with occlusive dressings (e.g., wet wraps) - 2 weeks Systemic corticosteroids (inhaled and intraocular permitted) - 4 weeks Immunosuppressive or immunomodulatory drugs (e.g., cyclosporine A, oral tacrolimus, cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil, JAK inhibitors) - 4 weeks or 5 half-lives (whichever is longer) Biologics and biosimilars (e.g., etanercept, adalimumab, infliximab, omalizumab) - 8 weeks or 5 half-lives (whichever is longer) Dupilumab - 10 weeks Live (attenuated) vaccine - 4 weeks Alternative medicine for AD (e.g., traditional Chinese medicine) - 2 weeks For participants with planned live (attenuated) vaccination during the study, consultation with a pediatrician will determine whether vaccination should be postponed until study completion or administered before study start without compromising health. Inactivated vaccines (e.g., diphtheria, tetanus, pertussis (DPT), hepatitis A, hepatitis B, inactivated polio vaccine (IPV), haemophilus influenzae type B, meningococcal, pneumococcal, influenza) are permitted.\n\n* Participants who, after a full 16-week treatment course with dupilumab, experienced worsening of AD or failed to achieve minimal improvement (e.g., \\\u003C= 10% reduction in EASI or no reduction in IGA).\n* History of lymphoproliferative disease or malignancy of any organ system before the screening visit.\n* History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, e.g., monoclonal antibody) or any study treatment excipients.\n* Known or suspected primary immunodeficiency.\n* History of, or current confounding skin condition (e.g., Netherton syndrome, psoriasis, contact dermatitis, dermatitis herpetiformis, erythroderma, ichthyosis, scabies) that may interfere with study assessments.\n* Any medical condition (e.g., serious cardiac, hepatic, pulmonary \\[including uncontrolled asthma\\], or hematologic disease) or clinically relevant laboratory abnormality during screening that may place the participant at significant risk or interfere with study assessments (e.g., poor venous access or needle phobia). Note: Laboratory tests with abnormal results may be repeated once during screening; the last value will determine eligibility.\n\nUncontrolled asthma defined as one or more of the following:\n\n* Asthma exacerbation requiring hospitalization since birth (\\\u003C=12 months of age) or within the preceding 12 months (\\>12 months of age)\n* Daytime asthma symptoms \\>2 times per week during the preceding 3 months\n* Nighttime awakenings \\>2 times per month during the preceding 3 months\n* Asthma exacerbation requiring oral corticosteroids or additional Short-Acting\n* Beta-Agonist (SABA) inhalers \\>2 times per week during the preceding 3 months\n\n  * Planned or expected major surgical procedure during the clinical study.\n  * Planned or anticipated use of prohibited medications during the study.\n  * Currently participating or participated in another clinical study of an investigational drug or device within the past 8 weeks (or 5 half-lives, whichever is longer) before the screening visit, or currently in an exclusion period from a previous clinical study.","ALL","6 Months","23 Months",{"count":21,"type":22},35,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The primary objective of the study is to assess the pharmacokinetics (PK) and safety of nemolizumab in pediatric participants (aged 6-23 months) with moderate-to-severe atopic dermatitis (AD) who are not adequately controlled with topical treatments.",[28],"Moderate-to-Severe Atopic Dermatitis","RECRUITING","2026-08-12",{"date":32,"type":33},"2026-08-14","ACTUAL",{"date":35,"type":33},"2026-07-13",{"date":37,"type":22},"2028-07-15",{"name":39,"class":40},"Galderma R&D","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100636484","study-to-evaluate-the-safety-of-retreatment-with-restylane-lyft-with-lidocaine-for-augmentation-of-the-chin-region-100636484","NCT07566286","Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region","A Prospective, Multicenter Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile","Inclusion Criteria:\n\n1. Males or non-pregnant, non-breastfeeding females, 22 years of age or older.\n2. Intent to receive treatment for augmentation and correction of retrusion in the chin region.\n\nExclusion Criteria:\n\n1. Known\u002Fprevious allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram positive bacterial proteins.\n2. Known\u002Fprevious allergy or hypersensitivity to local anesthetics, e.g. lidocaine or other amide-type anesthetics.\n3. Previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions.\n4. Previous facial surgery (including facial aesthetic surgery and liposuction), below the level of the horizontal line from subnasale.\n5. Any previous aesthetic procedures or implants.\n6. Presence of any disease or lesions near or on the area to be treated.",true,"22 Years",{"count":52,"type":22},100,[54],"NA","The primary objective of this study is to evaluate the safety of Restylane Lyft with Lidocaine for augmentation of the chin region 3 months after retreatment.",[57],"Chin Augmentation",{"date":32,"type":33},{"date":60,"type":33},"2026-06-03",{"date":62,"type":22},"2028-02-28",{"name":39,"class":40},8,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100651611","phase-3-randomized-double-blind-placebo-controlled-study-of-nemolizumab-in-chinese-subjects-with-moderate-to-severe-atopic-dermatitis-100651611","NCT07762833","Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis","A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Chinese Subjects With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\n1. Chinese subjects aged ≥ 12 years at the screening visit.\n2. Chronic AD for at least 2 years before the screening visit and confirmed according to American Academy of Dermatology Consensus Criteria (Eichenfield 2014, Appendix 1) at the time of the screening visit.\n3. EASI score ≥ 16 at both the screening and baseline visits.\n4. IGA score ≥ 3 (based on the IGA scale ranging from 0 to 4, in which 3 is moderate and 4 is severe) at both the screening and baseline visits.\n5. AD involvement ≥ 10% of body surface area (BSA) at both the screening and baseline visits.\n6. Peak (maximum) pruritus NRS score of at least 4.0 at the screening and baseline visit:\n\n   * Screening PP-NRS score will be determined by a single PP-NRS assessment (score ranging from 0 to 10) for the 24-hour period immediately preceding the screening visit.\n   * Baseline PP-NRS score will be determined based on the average of daily PP-NRS scores (score ranging from 0 to 10) during the 7 days immediately preceding baseline (rounding not permitted). A minimum of 4 daily scores out of the 7 days immediately preceding baseline is required for this calculation.\n7. Documented history (within 6 months before the screening visit) of inadequate response to topical medications (TCS with or without TCI). Acceptable documentation includes patient records with information on TCS (with or without TCI) prescription and treatment outcome, or written documentation of the conversation with the subject's treating physician, if different than the investigator.\n\n   Inadequate response to TCS treatments (with or without TCI) is defined as:\n   1. Failure to achieve or maintain remission or low disease activity (equivalent to IGA ≤ 2) despite treatment with a regimen of a medium- or high-potency TCS\\* (with or without TCI), applied for at least 4 weeks or for the maximum duration per prescribing information; or\n   2. Requirement of a long-term treatment (\\> 4 weeks) with a high-potency TCS\\* (with or without TCI) to achieve or maintain remission or low disease activity (equivalent to IGA ≤ 2); Note: If subjects had received a TCI in addition to a TCS, documentation on failure to achieve or maintain remission or low disease activity (equivalent to IGA ≤ 2) is also required.\n\n   or c. If documentation of inadequate response to topical treatments is not available, subjects with a documented recent course of systemic treatment or phototherapy for AD (within 6 months before the visit) will also be considered as inadequate responders to topical treatments.\n\n   If documentation is inadequate, subjects may be rescreened after such documentation is obtained.\n\n   \\* Refer to Appendix 2 for a listing of permitted medium and high-potency TCS medications that are commercially available in China.\n8. Agree to apply an authorized TCS ± TCI from the screening visit and throughout the study as determined appropriate by the investigator.\n9. Women of childbearing potential (WOCBP) must agree either to commit to true abstinence throughout the study and for 12 weeks after the last IP injection, when this is in line with the preferred and usual lifestyle of the subject, or to use an effective and approved method of contraception throughout the study and for 12 weeks after the last IP injection. This criterion also applies to a prepubertal female subject who begins menses during the study. Adequate and approved methods of contraception applicable for the subject and\u002For her partner are defined below:\n\n   * Progestogen-only oral hormonal contraception\n   * Combination of male condom with cap, diaphragm, or sponge with spermicide\n   * Combined (estrogen- and progestogen-containing) oral, intravaginal, or transdermal hormonal contraception (double barrier methods)\n   * Injectable or implanted hormonal contraception\n   * Intrauterine devices\n   * Bilateral tubal ligation or tube insert (such as the Essure system) at least 3 months before the study\n   * Vasectomy of partner at least 3 months before the study W Emergency contraception to prevent pregnancy after unprotected intercourse are not acceptable methods for routine use.\n10. Female subjects of non-childbearing potential must meet one of the following criteria:\n\n    * Absence of menstrual bleeding for 1 year prior to screening without any other medical reason, confirmed with follicle stimulating hormone (FSH) level in the postmenopausal range.\n    * Documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 3 months before the study Note: Bilateral tubal ligation is not accepted as a reason for non-childbearing potential.\n11. Subject willing and able to comply with all of the time commitments and procedural requirements of the clinical study protocol.\n12. Understand and sign an informed consent form\u002Fassent form before any investigational procedure(s) are performed\n\nExclusion Criteria:\n\n1. Body weight \\\u003C 30 kg.\n2. Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics, or antifungals within 2 weeks before the baseline visit.\n3. Known or suspected history of immunosuppression, or unusually frequent, recurrent, severe, or prolonged infections, as per investigator's judgment.\n4. History of lymphoproliferative disease or history of malignancy of any organ system within the last 5 years, except for (1) basal cell carcinoma, squamous cell carcinoma in situ (Bowen's disease), or carcinomas in situ of the cervix that have been treated and have no evidence of recurrence in the last 12 weeks before the baseline visit, or (2) actinic keratoses that have been treated.\n5. Presence of confounding skin condition that may interfere with study assessments (e.g. Netherton syndrome, psoriasis, cutaneous T-cell lymphoma \\[mycosis fungoides or Sezary syndrome\\], contact dermatitis, chronic actinic dermatitis, dermatitis herpetiformis).\n6. Pregnant women (positive serum pregnancy test result at the screening visit or positive urine pregnancy test at the baseline visit), breastfeeding women, or women planning a pregnancy during the clinical study.\n7. Any medical (e.g., serious cardiac\u002Fhepatic\u002Flung \\[including uncontrolled asthma\\]\u002Fhematologic disease) or psychological condition or any clinically relevant laboratory abnormalities, such as but not limited to elevated ALT or AST (\\> 3 × upper limit of normal \\[ULN\\]) in combination with elevated bilirubin (\\> 2 × ULN), during the screening period that may put the subject at significant risk according to the investigator's judgment, if he\u002Fshe participates in the clinical study, or may interfere with study assessments (e.g. poor venous access or needle-phobia).\n8. Planned or expected major surgical procedure during the clinical study.\n9. Having received any of the following treatments within the specified timeframe before the baseline visit:\n\n   Treatment(s) Timeframe Coal tar products 2 weeks Topical PDE-4 inhibitor 2 weeks Non-authorized TCS 2 weeks Topical medications, including authorized TCS\u002FTCI, with occlusive dressings (e.g., wet wraps) 2 weeks Systemic corticosteroids (corticosteroid inhalers and intraocular corticosteroids are permitted) 4 weeks Phototherapy or tanning beds 4 weeks Immunosuppressive or immunomodulatory drugs (e.g., cyclosporin A, oral tacrolimus, cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil, Janus kinase inhibitors) 4 weeks or 5 half-lives (whichever is longer) Biologics and their biosimilars (e.g., etanercept, adalimumab, infliximab, omalizumab) 8 weeks or 5 half-lives (whichever is longer) Dupilumab 10 weeks Live-attenuated vaccines 4 weeks Drugs with a sedative effect such as benzodiazepines, imidazopyridines, barbiturates, sedative antidepressants (e.g., amitriptyline), SSRIs (e.g., paroxetine), or SNRIs, except if these treatments were taken at a stable dose for at least 3 months before screening (Stable treatment with antihistamines with sedative effect is allowed.) 1 week Gabapentinoids (e.g., gabapentin, pregabalin) 4 weeks Cannabinoids 2 weeks Cannabinoids alternative medicine for AD (e.g., traditional Chinese medicine) 2 weeks Aromatic Hydrocarbon Receptor \\[AhR\\] modulator (e.g. tapinarof ) 2 weeks\n\n   Abbreviations: AD = atopic dermatitis; PDE-4 = phosphodiesterase-4; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCI = topical calcineurin inhibitor; TCS = topical corticosteroid.\n\n   Note: Subjects should not interrupt ongoing treatment with medications important for the subject's health for the sole purpose of participating in this study.\n10. Subjects unwilling to refrain from using prohibited medications during the clinical study.\n11. Requiring rescue therapy for AD during the screening period or expected to require systemic rescue therapy during the treatment period.\n12. Previous treatment with nemolizumab.\n13. History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, e.g., monoclonal antibody) or to any of the IP excipients.\n14. History of intolerance to low- or medium-potency TCS or for whom TCS is not advisable (e.g., hypersensitivity, significant skin atrophy).\n15. Currently participating or participated in any other study of an investigational drug or device, within the past 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) before the screening visit.","12 Years",{"count":74,"type":22},240,[76],"PHASE3","This is a bridging study only for Chinese subjects. The goal of this clinical trial is to learn if drug Nemolizumab works to treat moderate to severe AD in over 12 years old male and female. It will also learn about the safety of drug Nemolizumab.\n\nResearchers will compare drug Nemolizumab to a placebo (a look-alike substance that contains no drug) to see if drug Nemolizumab works to treat moderate to severe atopic dermatitis.\n\nParticipants will:\n\nTake drug Nemolizumab or a placebo at baseline and every 4 weeks followed, Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms and the disease situation.",[79],"Atopic Dermatitis",[28],"NOT_YET_RECRUITING","2026-08-10",{"date":84,"type":33},"2026-08-13",{"date":86,"type":22},"2026-09-28",{"date":88,"type":22},"2028-09-28",{"name":39,"class":40},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":97,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},"100592068","real-world-experience-on-using-nemolizumab-in-the-treatment-of-moderate-to--severe-prurigo-nodularis-in-adults-100592068","NCT06988618","Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults","RE-UNITE PN","Inclusion Criteria:\n\n* Participants who, according to the treating physician's decision and in line with the local package label, are newly initiated on nemolizumab (Nemluvio®) for the treatment of PN.\n* Participants greater than or equal to (\\>=) 18 years of age.\n* Participants who signed the written informed consent form (ICF).\n\nExclusion Criteria:\n\n* Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label;\n* Participants who received treatment with a drug under clinical development\u002F investigation within 3 months prior to baseline.\n* Participants who received nemolizumab previously.\n* Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and\u002For to complete the study questionnaires.","18 Years",{"count":99,"type":22},600,"OBSERVATIONAL","The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.",[103],"Prurigo Nodularis","2026-05-28",{"date":106,"type":33},"2026-06-01",{"date":108,"type":33},"2025-08-11",{"date":110,"type":22},"2027-11-30",{"name":39,"class":40},51,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":97,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},"100596609","phase-2-a-study-of-nemolizumab-for-the-treatment-of-adults-with-systemic-sclerosis-100596609","NCT07047690","A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis","A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Nemolizumab in Adult Patients With Systemic Sclerosis","Inclusion Criteria:\n\n1. Participant must be 18 years of age or older, at the time of signing the Informed Consent Form.\n2. Classification of systemic sclerosis (SSc) as defined by the 2013 American College of Rheumatology \\[ACR\\]\u002FEuropean League Against Rheumatism \\[EULAR\\] criteria.\n3. Modified Rodnan Skin Score.\n\n   1. Diffuse cutaneous systemic sclerosis (DcSSc) participants and modified Rodnan Skin Score (mRSS) of greater than equal to (\\>=)12 and less than (\\\u003C)30 at both screening and baseline\n   2. Limited cutaneous systemic sclerosis (LcSSc) participants with mRSS \\>=8 at both screening and baseline. LcSSc participants with positive anti-centromere at screening are excluded.\n4. Disease duration in DcSSc participants \\\u003C= 5 years from screening and LcSSc participants \\\u003C=2 years from screening is defined as the time from the first non-Raynaud's phenomenon manifestation of SSc.\n5. Participants are permitted to receive the following background therapies stable for at least 3 months prior to baseline, including any combination of the following:\n\n   1. Nintedanib (\\\u003C150mg twice daily) and\u002For\n   2. One of the following:\n\n      1. Methotrexate (MTX) (\\\u003C25mg weekly) or\n      2. Mycophenolate mofetil (MMF), mycophenolate sodium (MPS), or mycophenolic acid (MPA) (\\\u003C3000mg daily MMF, \\\u003C2160mg daily for MPS or MPA) NOTE: MTX should not be used in combination with MMF\u002FMPS\u002FMPA\n6. Participants with evidence for active or progressive disease.\n7. Men (whose female partner can become pregnant) and women of childbearing potential will be required to use effective means of contraception or commit to true abstinence, when this is in line with preferred and usual lifestyle of the participant, during the study and for at least 12 weeks after receiving the last study treatment.\n8. Female participants of non-childbearing potential\n9. Signed informed consent\n\nExclusion Criteria:\n\n1. Anti-centromere antibody positive at screening for participants with LcSSc.\n2. Anti-RNA polymerase 3 antibody positive for participants with a disease duration \\>18months.\n3. Creatinine clearance \\\u003C30 milli liter per minute \\[ml\u002Fmin\\] (calculated by Cockcroft-Gault formula).\n4. Positive serology results (hepatitis B surface antigen \\[HBsAg\\] or hepatitis B core antibody \\[HbcAb\\], hepatitis C \\[HCV\\] antibody with positive confirmatory test for hepatitis C virus \\[HCV\\] antibody with positive HCV RNA, or human immunodeficiency virus \\[HIV\\] antibody).\n5. FVC \\\u003C50% of predicted normal value, and DLCO \\\u003C40% of predicted normal value (corrected for Hb) at screening and baseline.\n6. Known diagnosis of clinically significant respiratory disorders other than ILD, including severe chronic obstructive pulmonary disease, severe asthma, recent (within 3 months) severe respiratory infections or history of recurrent respiratory infections, smoking, and any other respiratory condition that, in the opinion of the investigator, could interfere with the study or pose a risk to the participant.\n7. Currently listed and\u002For anticipated to be listed for lung transplantation within the next 12 months.\n8. Cardiovascular disease with clinically significant arrhythmia requiring therapy, congestive heart failure (New York Heart Association Class III-IV functional capacity), unstable angina, uncontrolled hypertension, Cor pulmonale, or symptomatic pericardial effusion.\n9. History of myocardial infarction in the last 6 months prior to screening.\n10. Pulmonary hypertension WHO Functional Class III or higher (as defined by WHO 2009) requiring treatment.\n11. Clinical signs of severe malabsorption in the opinion of the investigator or needing parenteral nutrition.\n12. History of scleroderma renal crisis (SRC) 6 months prior to screening.\n13. Participants with underlying chronic liver disease (Child Pugh A, B, C hepatic impairment).\n14. Body weight of \\\u003C30.0 kilogram (Kg) at screening or BL\n15. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed, or unwilling to use appropriate contraception measures during the study period\n16. Previous treatment with nemolizumab\n17. Participants with the primary diagnosis of a rheumatic autoimmune disease other than SSc, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, polymyositis, dermatomyositis, systemic vasculitis, Sjogren's syndrome, anti-synthetase syndrome, or mixed CTD, as determined by the investigator with consultation of the medical monitors\n18. Systemic sclerosis-like illness including but not limited to localized scleroderma (morphea), eosinophilic fasciitis, sclerodermoid graft-versus-host disease, fibro mucinous conditions (scleredema, scleromyxedema), scleroderma-like conditions that are associated with environmental chemical and drug exposure (e.g., toxic rapeseed oil, vinyl chloride, bleomycin, gadolinium-based contrast agents \\[nephrogenic systemic fibrosis\\], or due to metabolic disease)\n19. History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, e.g., monoclonal antibody) or to any of the study treatment excipient\n20. Known active bacterial, viral, fungal, or any major episode of infection requiring hospitalization or treatment with IV antibiotics or antivirals within 4 weeks prior to screening, or oral antibiotics within 2 weeks prior to screening. Participants may be rescreened once the infection has resolved.\n21. History of a primary immunodeficiency\n22. History of Bone Morrow Transplantation. Chimeric Antigen Receptor (CAR)-T Cell Therapy or any other genetically engineering cells\n23. History of lymphoproliferative disease or history of malignancy of any organ system within the last 5 years, except for (1) basal cell carcinoma, squamous cell carcinoma in situ (Bowen's disease), or carcinomas in situ of the cervix that have been treated and have no evidence of recurrence in the last 12 weeks before the BL visit, or (2) actinic keratoses that have been treated\n24. History of alcohol or substance abuse dependence or any condition that, in the investigator's opinion makes the participant unreliable to following instructions and complete the study\n25. In the opinion of the investigator, the participant has any medical condition, including clinically significant pulmonary abnormalities, or psychological condition,or clinically significant laboratory abnormalities that could pose undue risk to the participant, prevent study completion or adversely affect the validity or interpretability of the study measurements or interfere with the study assessments, or impede the participant's ability to complete the study.\n26. Participant has not adhered to the restrictions in select treatments prior to screening or is not expected to be compliant with restrictions during the study",{"count":121,"type":22},162,[25],"The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this target population.",[125],"Systemic Sclerosis",[127,128,129],"Limited Cutaneous Systemic Sclerosis","Diffuse Cutaneous Systemic Sclerosis","Interstitial Lung Disease","2026-03-26",{"date":132,"type":33},"2026-03-31",{"date":134,"type":33},"2026-02-20",{"date":136,"type":22},"2028-07-23",{"name":39,"class":40},3,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":156,"locationsCount":157},"100592067","real-world-experience-using-nemolizumab-in-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-adolescents--adults-100592067","NCT06988605","Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults","RE-UNITE AD","Inclusion Criteria:\n\n* Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®).\n* Adolescent and adult participants aged \\>=12 years with moderate-to-severe AD.\n* Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.\n\nExclusion Criteria:\n\n* Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label.\n* Participants who received treatment with a drug under clinical development\u002Finvestigation within 3 months prior to baseline.\n* Participants who received nemolizumab previously.\n* Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and\u002For to complete the study questionnaires.",{"count":147,"type":22},1000,"The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.",[79],"2026-03-11",{"date":152,"type":33},"2026-03-13",{"date":154,"type":33},"2025-07-14",{"date":110,"type":22},{"name":39,"class":40},108,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":165,"minAge":166,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":41},"100623622","a-study-to-characterize-human-skin-changes-from-biostimulator-treatments-via-non-invasive-imaging-100623622","NCT07399028","A Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging","A Single-center, Open-label Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging","Inclusion Criteria:\n\n* Adult subjects aged 45-65 years old\n* Females only\n* Subject with moderate-to-severe cheek wrinkles on the GCWS\n* Subject with intent to undergo correction of cheek wrinkles on both sides of the face\n* Subject who in the opinion of the Investigator would need 3 treatments for optimal clinical outcomes\n* Subject willing to be photographed at each visit.\n* Subjects willing to stop using current facial skincare products for the duration of the study.\n* Subject willing to replace the current facial skincare products with the provided facial skincare products, including cleanser, moisturizer and sunscreen, until study completion.\n* Ability to read, understand and give consent for participation in the study.\n* Agreement to adhere to the procedures and requirements of the study and to report to the site on the day(s) and at the time(s) scheduled for the assessments.\n\nExclusion Criteria:\n\n* Subjects with a history of allergy or hypersensitivity to any ingredient of the treatment products.\n* Previous tissue-augmenting therapy, contouring, or revitalization treatment in the face, except lips.\n* Previous treatment\u002Fprocedure in the face in the previous 6 months that, in the Investigator's opinion, would interfere with the study injections and\u002For study assessments or exposed the study subject to undue risk by study participation, or planning to undergo any of these procedures affecting the treatment area at any time during the study.\n* Subjects with any medical condition that, in the opinion of the Investigator, would make the subject unsuitable for inclusion.","FEMALE","45 Years","65 Years",{"count":169,"type":22},25,[54],"Adult subjects with moderate-to-severe cheek wrinkles will be treated with Sculptra for correction of fine lines and wrinkles in the cheek area.",[173,174,175],"Volume Deficiency in the Mid-Face","Skin Laxity","Photo-aged Skin","2026-02-02",{"date":178,"type":33},"2026-02-10",{"date":180,"type":33},"2025-10-21",{"date":182,"type":22},"2026-09",{"name":39,"class":40},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":165,"minAge":50,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":206},"100619267","a-clinical-study-to-assess-histological-changes-from-treatment-of-poly-l-lactic-acid-biostimulator-on-women-at-various-menopausal-stages-100619267","NCT07342400","A Clinical Study to Assess Histological Changes From Treatment of Poly L-lactic Acid Biostimulator on Women at Various Menopausal Stages","A Multi-center, Prospective Clinical Study to Assess Histological Changes From Treatment of Poly L-lactic Acid Biostimulator on Women at Various Menopausal Stages","Inclusion Criteria:\n\n* Subjects diagnosed with symmetrical, moderate-to-severe cheek wrinkles on each side of the face as assessed via the Galderma Cheek Wrinkles Scale.\n* Subject with intent to undergo correction of cheek augmentation or contour deficiencies\n* Subjects willing to have a 3-mm punch biopsy on each preauricular side\n* Subjects willing to maintain the current lifestyle, daily routine (e.g., diet, exercise, sleep, etc.), and a stable Body Mass Index (BMI, ± 5 kg\u002Fm2) throughout the study\n* Ability of giving consent for participation in the study.\n* Agreement to adhere to the procedures and requirements of the study and to report to the institute on the day(s) and at the time(s) scheduled for the assessments.\n\nExclusion Criteria:\n\n* Subjects with asymmetrical severity or unidentical cheek wrinkle score between 2 sides of the cheek.\n* Subjects with a history of allergy or hypersensitivity to any ingredient of the treatment products.\n* Previous tissue-augmenting therapy, contouring, or revitalization treatment in the face, except lips.\n* Previous treatment\u002Fprocedure in the face in the previous 6 months that, in the Investigator's opinion, would interfere with the study injections and\u002For study assessments or exposed the study subject to undue risk by study participation, or planning to undergo any of these procedures affecting the treatment area at any time during the study.\n* Subjects with any medical condition that, in the opinion of the Investigator, would make the subject unsuitable for inclusion.",{"count":192,"type":22},40,[54],"To assess protein expression stimulated by poly L-lactic acid (PLLA) via punch biopsy at each follow-up visits compared to Baseline.",[196,197],"Cheek Wrinkles","Menopausal Women","2026-01-13",{"date":200,"type":33},"2026-01-15",{"date":202,"type":33},"2025-08-12",{"date":204,"type":22},"2026-11",{"name":39,"class":40},2,{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":215,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":41},"100607273","phase-3-a-study-to-compare-the-efficacy-safety-and-pharmacokinetics-of-trifarotene-50-mcgg-cream-in-chinese-subjects-with-acne-vulgaris-100607273","NCT07186413","A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg\u002Fg Cream in Chinese Subjects With Acne Vulgaris","A Multicenter, Randomized, Double-blinded, Parallel-group, Vehicle-controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg\u002Fg Cream in Chinese Subjects With Acne Vulgaris","AKLIEF","Inclusion Criteria:\n\nParticipants must meet the following criteria to be included in the study:\n\n1. Male or female Chinese participants aged 9 years or older at the screening visit.\n2. A minimum of 20 inflammatory lesions and 25 non-inflammatory lesions on the face at Screening and Baseline.\n3. Facial acne vulgaris severity grade 3 (moderate) on the IGA scale at Screening and Baseline.\n4. A minimum of 20 inflammatory lesions and 20 non-inflammatory lesions but no more than 100 non-inflammatory lesion counts on the trunk (shoulders, upper back, and upper anterior chest) reachable for self-application of investigational product by the participant at Screening and Baseline (optional criterion for participant between 9 and 11 years of age).\n5. Acne vulgaris severity grade 3 (moderate) on the PGA scale at Screening and Baseline visits on trunk (shoulders, upper back and upper anterior chest) reachable for self-application of investigational product by the participant (optional criterion for participants between 9 and 11 years of age).\n6. Female participants of non-childbearing potential, i.e., premenstrual, or postmenopausal. Postmenopausal participants must meet one criterion at Screening:\n\n   * Absence of menstrual bleeding for 1 year before screening with no other medical reason, confirmed with follicle-stimulating hormone level in the postmenopausal range.\n   * Documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 3 months before Screening.\n7. Female participants of childbearing potential (i.e., fertile, after menarche and until becoming postmenopausal unless permanently sterile) must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test (UPT) at the baseline visit (with a sensitivity of 25 international units per litre \\[IU\u002FL\\] or less). They must use at least 1 adequate and approved method of contraception throughout the study and for 1 month after the last dose of investigational product.\n8. Premenstrual participants who start menses during the study must use at least 1 adequate and approved method of contraception throughout the study and for 1 month after the last dose of investigational product.\n9. Willing and able to comply with all the time commitments and procedural requirements of the clinical study protocol.\n10. Understands and signs an informed consent form (ICF) at the screening visit, before any investigational procedures are performed.\n11. Participants who are younger than 18 years of age and whose parent\u002Flegal representative is willing\u002Fable to comply with the study requirements and understand\u002Fsign the ICF at the screening visit, before any investigational procedures are performed, will sign the assent ICF at the screening visit.\n12. At selected clinical sites: If a participant who is 18 years of age or older at the screening visit and agrees to participate in study photographs, verified by dating and signing a separate approved photography ICF. For participants younger than 18 years of age, an assent photography ICF signed by the participant in conjunction with a photography ICF signed by the parents(s)\u002Flegal representative at the screening visit.\n13. Participant is informed of terms pertaining to personal information protection and privacy and is willing to share personal information and data, in accordance with local regulations.\n\nExclusion Criteria:\n\nParticipants meeting the following criteria at the screening or baseline visits are ineligible to participate in this study:\n\n1. Pregnant women (positive serum pregnancy test result at the screening visit or positive UPT at the baseline visit), breastfeeding women, or women planning a pregnancy during the study or within 1 month after the last investigational product application.\n2. Severe forms of acne (e.g., acne conglobata, acne fulminans) or secondary acne form (e.g., chloracne, drug-induced acne) at the screening and baseline visits.\n3. More than 1 nodule on the face at the screening and baseline visits.\n4. More than 1 nodule on the trunk at the screening and baseline visits.\n5. Any acne cyst on the face at the screening and baseline visits.\n6. Any acne cyst on the trunk at the screening and baseline visits.\n7. Facial or truncal hair that may interfere with the study assessments according to investigator's judgment.\n8. Abnormal pigmentation, wound, scar, or tattoo on the face or on the shoulders, upper back, or chest that may interfere with the study assessments according to investigator's judgment.\n9. Any uncontrolled or serious disease or any medical or surgical condition that may interfere with the interpretation of the study results and\u002For put the participant at significant risk according to investigator's judgment.\n10. Abnormal laboratory test results at the screening visit (hematology, comprehensive metabolic panel, and urinalysis) judged as clinically significant by the investigator (to be checked before the baseline visit), which may interfere with the interpretation of the study results and\u002For put the participant at significant risk (e.g., elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (\\> 3 × upper limit of normal \\[ULN\\])).\n11. Known allergies or hypersensitivities to any component of the formulation of the investigational products (trifarotene 50 mcg\u002Fg cream or vehicle cream; see Investigator's Brochure).\n12. Previously participated in any trifarotene cream clinical study.\n13. Current participation in any other clinical study of a drug or device OR past participation within 30 days before the baseline visit.\n14. Alcohol or drug abuse or substance dependence within 12 months before the screening visit.\n15. Inability or unwillingness to undergo multiple venipunctures because of poor tolerability or venous access.\n16. Loss of over 500 mL of blood or blood donation within the last 3 months before the screening visit.\n17. Having received prohibited medication or treatment during the study.\n18. Exposure to excessive ultraviolet (UV) radiation within 1 month before the baseline visit.\n19. Unwillingness to avoid excessive or prolonged exposure to UV light (i.e., occupational exposure to the sun, sunbathing, tanning bed use, phototherapy) throughout the study.\n20. Any drug that in the opinion of the investigator may interfere with the study assessments or exacerbate acne, i.e., lithium, halogens, haloperidol, hydantoin, phenobarbital, Vitamin B12, androgens.\n21. Unwillingness to refrain from prohibited medication during the clinical study as defined by protocol.\n22. Participant vulnerability (such as freedom deprivation, mental disease, those incapable of giving consent) as defined in Section 1.61 of the International Council for Harmonization Guideline for Good Clinical Practice (GCP).\n23. More than 1 participant sharing the same household.\n24. Clinical site personnel, close relatives of the clinical site personnel (e.g., parents, children, siblings, or spouse), employees, or close relatives of employees of the Sponsor company.","9 Years",{"count":217,"type":22},561,[76],"The primary objective is to assess the efficacy of trifarotene 50 microgram per gram (mcg\u002Fg) cream versus vehicle cream when applied once daily (QD) for 12 weeks in Chinese participants with moderate facial and truncal acne vulgaris.",[221],"Acne Vulgaris","2025-11-18",{"date":224,"type":33},"2025-11-21",{"date":226,"type":33},"2025-09-23",{"date":228,"type":22},"2026-12-31",{"name":39,"class":40},""]